Novel sequential treatment with palbociclib enhances the effect of cisplatin in RB-proficient triple-negative breast cancer

BACKGROUND: Triple-negative breast cancer (TNBC) is a highly aggressive malignancy that lacks sensitivity to chemotherapy, endocrine therapy or targeted therapy. CDK4/6 inhibitors, combined with endocrine therapy, have been shown to be effective in postmenopausal women with HR-positive, HER2-negativ...

Descripción completa

Detalles Bibliográficos
Autores principales: Huang, Yajing, Wu, Hao, Li, Xingrui
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Primary Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7552520/
https://www.ncbi.nlm.nih.gov/pubmed/33061853
http://dx.doi.org/10.1186/s12935-020-01597-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7552520/
https://www.ncbi.nlm.nih.gov/pubmed/33061853
http://dx.doi.org/10.1186/s12935-020-01597-x

Ejemplares similares